FrancophonIA/ELRC3.0 huggingface dataset:
English: • Weight gain
Croatian: • povećanje tjelesne težine
English: EU/1/09/588/001 EU/1/09/588/002
Croatian: EU/1/09/588/001 EU/1/09/588/002 EU/1/09/588/003
English: Systemic Symptoms (DRESS)
Croatian: Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS) (učestalost nepoznata)
English: Olanzapine Glenmark Europe 20 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL' debossed on one side and ‘F' debossed on other side.
Croatian: Olanzapin Glenmark Europe 20 mg: žute, okrugle, plosnate raspadljive tablete za usta kosih rubova, s utisnutom oznakom ‘OL' na jednoj i ‘F' na drugoj strani.
English: Olanzapine Glenmark Europe 10 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL' debossed on one side and ‘D' debossed on other side.
Croatian: Olanzapin Glenmark Europe 10 mg: žute, okrugle, plosnate raspadljive tablete za usta kosih rubova, s utisnutom oznakom ‘OL' na jednoj i ‘D' na drugoj strani.
English: Olanzapine Glenmark Europe 15 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL' debossed on one side and ‘E' debossed on other side.
Croatian: Olanzapin Glenmark Europe 15 mg: žute, okrugle, plosnate raspadljive tablete za usta kosih rubova, s utisnutom oznakom ‘OL' na jednoj i ‘E' na drugoj strani.
English: • Prostate problems
Croatian: • pojačani umor
English: MARKETING AUTHORISATION NUMBER(S) EU/1/09/588/001
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/09/588/001
English: Olanzapine Glenmark Europe orodispersible tablets are for oral use.
Croatian: Olanzapin Glenmark Europe raspadljive tablete za usta uzimaju se kroz usta.
English: Very rare side effects (may affect up to 1 in 10,000) include:
Croatian: Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10 000 osoba) uključuju:
English: MARKETING AUTHORISATION NUMBER(S) EU/1/09/588/007
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/09/588/007
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 20 mg orodispersible tablets
Croatian: NAZIV LIJEKA Olanzapin Glenmark Europe 20 mg raspadljive tablete za usta
English: • Abnormal rhythms of the heart.
Croatian: • poremećaj srčanog ritma
English: Yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘D' debossed on one side.
Croatian: Žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘OL' na jednoj i ‘D' na drugoj strani.
English: Olanzapine Glenmark Europe 20 mg orodispersible tablets Olanzapine
Croatian: Olanzapin Glenmark Europe 20 mg raspadljive tablete za usta olanzapin
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 10 mg orodispersible tablets
Croatian: NAZIV LIJEKA Olanzapin Glenmark Europe 10 mg raspadljive tablete za usta
English: Olanzapine Glenmark Europe 5 mg orodispersible tablets Olanzapine
Croatian: Olanzapin Glenmark Europe 5 mg raspadljive tablete za usta olanzapin
English: Olanzapine Glenmark Europe 15 mg orodispersible tablets Olanzapine
Croatian: Olanzapin Glenmark Europe 15 mg raspadljive tablete za usta olanzapin
English: Uncommon side effects (may affect up to 1 in 100 people) include:
Croatian: Manje česte nuspojave (mogu se pojaviti u manje od 1 na 100 osoba) uključuju:
English: Olanzapine Glenmark Europe 10 mg orodispersible tablets Olanzapine
Croatian: Olanzapin Glenmark Europe 10 mg raspadljive tablete za usta olanzapin
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 5 mg orodispersible tablets
Croatian: NAZIV LIJEKA Olanzapin Glenmark Europe 5 mg raspadljive tablete za usta
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 15 mg orodispersible tablets
Croatian: NAZIV LIJEKA Olanzapin Glenmark Europe 15 mg raspadljive tablete za usta
English: • Abdominal distension
Croatian: • nevoljno drhtanje
English: Common side effects (may affect up to 1 in 10 people) include:
Croatian: Česte nuspojave (mogu se pojaviti u manje od 1 na 10 osoba) uključuju:
English: 20 mg/day.
Croatian: 20 mg olanzapina.
English: Drug withdrawal syndrome neonatal (see section 4.6)
Croatian: dizartrija mucanje 11sindrom nemirnih nogu neuroleptički maligni sindrom (vidjeti dio 4.4)12
English: Talk to your doctor or pharmacist before you take Olanzapine Glenmark Europe - The use of Olanzapine Glenmark Europe in elderly patients with dememtia is not recommended as it may have serious side effects.
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete Olanzapin Glenmark Europe
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 10 mg olanzapine.
Croatian: Svaka raspadljiva tableta za usta sadrži 10 mg olanzapina.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each orodispersible tablet contains 15 mg Olanzapine Excipient with known effect: Each orodispersible tablet contains 0.69 mg of aspartame For the full list of excipients, see section 6.1
Croatian: Pomoćna tvar s poznatim učinkom: svaka raspadljiva tableta za usta sadrži 0,69 mg aspartama.
English: Common: Elevated cholesterol levels 15
Croatian: povišene razine kolesterola2,3
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each orodispersible tablet contains 10 mg olanzapine Excipient with known effect: Each orodispersible tablet contains 0.46 mg of aspartame For the full list of excipients, see section 6.1
Croatian: Pomoćna tvar s poznatim učinkom: svaka raspadljiva tableta za usta sadrži 0,46 mg aspartama.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 20 mg olanzapine
Croatian: Svaka raspadljiva tableta za usta sadrži 20 mg olanzapina.
English: Olanzapine Glenmark Europe 20 mg orodispersible tablets 17.
Croatian: Olanzapin Glenmark Europe 20 mg raspadljive tablete za usta
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 15 mg olanzapine.
Croatian: Svaka raspadljiva tableta za usta sadrži 15 mg olanzapina.
English: • Seizures
Croatian: • slabost
English: • stuttering,
Croatian: • mucanje;
English: Yellow coloured circular flat bevelled edge with ‘OL' debossed on one side and ‘F' debossed on other side.
Croatian: Žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘OL' na jednoj i ‘F' na drugoj strani.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 5 mg olanzapine.
Croatian: Svaka raspadljiva tableta za usta sadrži 5 mg olanzapina.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23 June 2017
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23. lipnja 2017.
English: It was to be available as a solution for infusion (drip) into a vein.
Croatian: Trebao je biti dostupan kao otopina za infuziju (drip) u venu.
English: What is Zafiride?
Croatian: Što je Zafiride?
English: The CHMP noted there was inadequate information in several areas of the application, including on the manufacture of the medicine, its testing in humans and animals and its safety.
Croatian: CHMP je primijetio da su podatci navedeni u nekoliko dijelova zahtjeva nedostatni, uključujući podatke o proizvodnji lijeka, njegovu testiranju na ljudima i životinjama te njegovoj sigurnosti.
English: In its letter notifying the Agency of the withdrawal of the application, the company stated that it would be unable to provide requested data on the medicine's manufacture within the required time frame.
Croatian: U svojem dopisu kojim je obavijestila Agenciju o povlačenju zahtjeva tvrtka je navela da unutar predviđenog vremenskog roka ne može dostaviti tražene podatke o proizvodnji lijeka.
English: Once attached to these receptors, it damages the walls of the blood vessels supplying the tumours, thereby helping to slow down the growth of the cancer.
Croatian: Nakon što se veže za te receptore, oštećuje stijenke krvnih žila koje opskrbljuju tumor, čime pomaže u usporavanju rasta stanica raka.
English: On 1 June 2017, MolMed S.p.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Zafiride for the treatment of advanced malignant pleural mesothelioma.
Croatian: Dana 1. lipnja 2017. tvrtka MolMed S.p.A. službeno je obavijestila Odbor za lijekove za humanu uporabu (CHMP) kako želi povući svoj zahtjev za odobrenje za stavljanje u promet lijeka Zafiride za liječenje uznapredovalog zloćudnog mezotelioma pleure.
English: What was Zafiride expected to be used for?
Croatian: Za što se Zafiride trebao koristiti?
English: The medicine was intended for those patients whose cancer has worsened within 6 months of treatment with cancer medicines including pemetrexed.
Croatian: Lijek je bio namijenjen onim bolesnicima u kojih se rak pogoršao u razdoblju od 6 mjeseci nakon liječenja lijekovima protiv raka, uključujući pemetreksed.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes using Zafiride.
Croatian: Tvrtka je obavijestila CHMP da nema posljedica za bolesnike koji su u ovom trenutku uključeni u klinička ispitivanja ili programe milosrdnog davanja lijekova u kojima se koristi lijek Zafiride.
English: With regard to the medicine's effectiveness, the main study did not show convincingly that Zafiride was better than placebo at prolonging lives in the intended patients.
Croatian: U pogledu učinkovitosti lijeka, glavnim ispitivanjem nije se uvjerljivo pokazalo da je Zafiride bolji od placeba u produljenju života bolesnika zahvaćenih tom bolešću.
English: How does Zafiride work?
Croatian: Kako djeluje Zafiride?
English: The company's application included results from a main study in 400 patients which looked at how long patients lived when treated with Zafiride in combination with other cancer medicines.
Croatian: Zahtjev tvrtke sadržavao je rezultate glavnog ispitivanja u kojemu je sudjelovalo 400 bolesnika i u kojemu se ispitivalo koliko dugo žive bolesnici koji su primili lijek Zafiride u kombinaciji s ostalim lijekovima za liječenje raka.
English: Zafiride was expected to be used for treating adults with advanced malignant pleural mesothelioma, a cancer of the lining of the lungs usually caused by exposure to asbestos.
Croatian: Zafiride se trebao primjenjivati za liječenje odraslih s uznapredovalim zloćudnim mezoteliomom pleure, tj. rakom plućne ovojnice koji je obično uzrokovan izloženošću azbestu.
English: Based on the review of the data, at the time of the withdrawal, the CHMP had concerns and was of the provisional opinion that Zafiride could not be approved for the second-line treatment of advanced malignant pleural mesothelioma in patients whose disease had worsened within 6 months of treatment with pemetrexed.
Croatian: Na temelju pregleda podataka u trenutku povlačenja CHMP je smatrao da postoje razlozi za zabrinutost te je njegovo privremeno mišljenje bilo da nije moguće dati odobrenje za lijek Zafiride za sekundarno liječenje uznapredovalog zloćudnog mezotelioma pleure u bolesnika čije se stanje pogoršalo u razdoblju od 6 mjeseci nakon liječenja pemetreksedom.
English: Zafiride is a medicine containing the active substance NGR-human tumour necrosis factor alpha.
Croatian: Zafiride je lijek koji sadržava djelatnu tvar NGR-ljudski tumor nekrotizirajući faktor alfa.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Zafiride did not outweigh its risks.
Croatian: Stoga je CHMP u vrijeme povlačenja smatrao kako koristi od lijeka Zafiride ne nadmašuju s njim povezane rizike.
English: The active substance in Zafiride is thought to work by attaching to targets called CD13 and TNF receptors, found on new blood vessels forming around tumours.
Croatian: Smatra se da djelatna tvar lijeka Zafiride djeluje tako da se veže za ciljna tijela koja se nazivaju receptori CD13 i TNF i nalaze se na novonastalim krvnim žilama koje se stvaraju oko tumora.
English: Zafiride was compared with placebo (a dummy treatment), and all patients in the study had previously been treated with pemetrexed-based chemotherapy.
Croatian: Djelovanje lijeka Zafiride uspoređeno je s placebom (prividnim liječenjem) i svi bolesnici koji su sudjelovali u tom ispitivanju prethodno su primali kemoterapiju ma bazi pemetrekseda.
English: Zafiride was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 3 June 2008 for malignant mesothelioma.
Croatian: Zafiride je uvršten na popis lijekova za rijetke bolesti dana 3. lipnja 2008. za zloćudni mezoteliom.
English: Here are some of the main results from these studies:
Croatian: U nastavku navodimo neke od glavnih rezultata tih ispitivanja:
English: The usual recommended infusion time is approximately 60 minutes.
Croatian: Uobičajeno preporučeno trajanje infuzije iznosi otprilike 60 minuta.
English: This was switched to a full marketing authorisation on 15 January 2015.
Croatian: To je odobrenje pretvoreno u potpuno odobrenje za stavljanje u promet 15. siječnja 2015.
English: This summary was last updated in 08-2019.
Croatian: Sažetak je posljednji put ažuriran u 8. 2019.
English: Further information on Vectibix can be found on the Agency's website ema.europa.eu/ medicines/human/EPAR/vectibix.
Croatian: Više informacija o lijeku Vectibix dostupno je na internetskim stranicama Agencije: ema.europa.eu/ medicines/human/EPAR/vectibix
English: The recommended dose of Vectibix is 6 mg per kilogram body weight given once every two weeks.
Croatian: Preporučena doza lijeka Vectibix iznosi 6 mg po kilogramu tjelesne težine i daje se jednom u dva tjedna.
English: As a result, these tumour cells can no longer receive the messages transmitted via EGFR that they need to grow and spread to other parts of the body.
Croatian: Kao rezultat toga, tumorske stanice više ne mogu primati poruke koje prenosi EGFR, a koje su im potrebne za rast i širenje u ostale dijelove tijela.
English: Vectibix received a conditional marketing authorisation valid throughout the EU on 3 December 2007.
Croatian: Lijek Vectibix dobio je uvjetno odobrenje za stavljanje u promet valjano u EU-u od 3. prosinca 2007.
English: Vectibix was originally given ‘conditional authorisation' because there was more evidence to come about the medicine.
Croatian: Za lijek Vectibix prvotno je izdano „uvjetno odobrenje” jer su se očekivali dodatni podatci o lijeku.
English: What measures are being taken to ensure the safe and effective use of Vectibix?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Vectibix?
English: The dose may need to be modified if severe skin reactions occur and treatment stopped if the reaction does not get better.
Croatian: Ako se pojave ozbiljne kožne reakcije, možda će biti potrebno promijeniti dozu, a liječenje treba prekinuti ako reakcija ne oslabi.
English: What is Vectibix and what is it used for?
Croatian: Što je Vectibix i za što se koristi?
English: Vectibix is a medicine for treating colorectal (bowel) cancer that has spread to other parts of the body.
Croatian: Vectibix je lijek za liječenje kolorektalnog karcinoma (raka debelog crijeva) koji se proširio u ostale dijelove tijela.
English: Patients receiving Vectibix also had a longer period of time without their disease getting worse: 6.4 months versus 4.6 months.
Croatian: Bolesnici koji su primali Vectibix imali su također dulje razdoblje bez pogoršanja bolesti: 6,4 mjeseca u odnosu na 4,6 mjeseci.
English: Other information about Vectibix
Croatian: Ostale informacije o lijeku Vectibix
English: It must not be used in patients with interstitial pneumonitis or pulmonary fibrosis (lung diseases).
Croatian: Ne smije se primjenjivati u bolesnika s intersticijskim pneumonitisom ili pulmonalnom fibrozom (plućnom bolešću).
English: An overview of Vectibix and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Vectibix i zašto je odobren u EU-u
English: Side effects reported with Vectibix are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Vectibix pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: The most common side effects with Vectibix (in more than 2 patients in 10) were diarrhoea, nausea (feeling sick), vomiting, constipation, abdominal pain (stomach ache), tiredness, fever, lack of appetite, paronychia (nail bed infection), rash, acneiform dermatitis (skin inflammation resembling acne), pruritus (itching), erythema (reddening of the skin) and dry skin.
Croatian: Najčešće nuspojave lijeka Vectibix (u više od 2 na 10 osoba) bile su proljev, mučnina, povraćanje, zatvor, abdominalna bol (bol u trbuhu), umor, vrućica, pomanjkanje apetita, paronihija (infekcije tkiva oko noktiju), osip, akneiformni dermatitis (kožna upala slična aknama), pruritus (svrbež), eritem (crvenilo kože) i suha koža.
English: The European Medicines Agency decided that Vectibix's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Vectibix nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
English: It contains the active substance panitumumab.
Croatian: Sadrži djelatnu tvar panitumumab.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vectibix have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Vectibix nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: As for all medicines, data on the use of Vectibix are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Vectibix kontinuirano se prate.
English: Treatment with Vectibix should be supervised by a doctor who has experience in the use of cancer therapy.
Croatian: Liječenje lijekom Vectibix mora biti pod nadzorom liječnika koji ima iskustva u primjeni terapije protiv raka.
English: Vectibix can only be obtained with a prescription.
Croatian: Vectibix se izdaje samo na recept.
English: What are the risks associated with Vectibix?
Croatian: Koji su rizici povezani s lijekom Vectibix?
English: For more information about using Vectibix, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Vectibix pročitajte uputu o lijeku odnosno obratite se liječniku ili ljekarniku.
English: It should only be started after the presence of wild-type RAS has been confirmed by an experienced laboratory using a validated test method.
Croatian: Prije početka liječenja potrebno je potvrditi prisutnost divljeg tipa gena RAS u iskusnom laboratoriju primjenom provjerene metode testiranja.
English: It was later confirmed that benefit is limited only to patients with wildtype RAS tumours.
Croatian: Kasnije je potvrđeno da je korist ograničena samo na bolesnike s tumorima koji sadrže divlji tip gena RAS.
English: Vectibix must not be used in patients who have had a severe or life-threatening hypersensitivity (allergic) reaction to panitumumab or any of the other ingredients in the past.
Croatian: Vectibix se ne smije primjenjivati u bolesnika koji su u prošlosti imali teške ili po život opasne reakcije preosjetljivosti (alergijske reakcije) na panitumumab ili bilo koji drugi sastojak.
English: Patients in this study (there was no comparator treatment) lived for an average of 11.2 months without their disease getting worse.
Croatian: Bolesnici obuhvaćeni tim ispitivanjem (u kojem nije bilo usporedne terapije) živjeli su u prosjeku 11,2 mjeseca bez pogoršanja bolesti.
English: Vectibix is available for infusion (drip) into a vein.
Croatian: Vectibix se primjenjuje intravenskom infuzijom (drip).
English: In studies, 93% of the patients receiving Vectibix had side effects affecting the skin, although most of these were mild or moderate.
Croatian: Tijekom ispitivanja pojavile su se nuspojave na koži u 93 % bolesnika koji su primali Vectibix, pri čemu je većina njih bila blaga ili umjerena.
English: The studies show Vectibix can be effective when used alone and together with the standard chemotherapy regimens FOLFOX (a combination of fluorouracil with folinic acid and the cancer medicine oxaliplatin) or FOLFIRI (fluorouracil with folinic acid and a different cancer medicine, irinotecan).
Croatian: Ispitivanja pokazuju da lijek Vectibix može biti učinkovit kada se primjenjuje samostalno i u kombinaciji sa standardnim kemoterapijskim protokolima FOLFOX (kombinacija fluorouracila s folinskom kiselinom i oksaliplatina, lijeka protiv raka) ili FOLFIRI (fluorouracil s folinskom kiselinom i irinotekan, drugi lijek protiv raka).
English: Why is Vectibix approved?
Croatian: Zašto je lijek Vectibix odobren?
English: This study involved patients with either wild-type or mutant RAS whose disease had got worse despite treatments that included a fluoropyrimidine, oxaliplatin and irinotecan.
Croatian: Tim su ispitivanjem bili obuhvaćeni bolesnici s divljim tipom ili mutiranim tipom gena RAS čija se bolest pogoršala usprkos terapijama koje su sadržavale fluoropiramidin, oksaliplatin i irinotekan.
English: Patients given these combinations lived for an average of 14.8 months and 12.8 months respectively without their disease getting worse.
Croatian: Bolesnici koji su primali te kombinirane terapije živjeli su u prosjeku 14,8 mjeseci, odnosno 12,8 mjeseci, bez pogoršanja bolesti.
English: Vectibix must not be used with oxaliplatin-containing chemotherapy in patients whose tumour contains the mutated RAS gene or for whom the RAS status is not known.
Croatian: Vectibix se ne smije primjenjivati s kemoterapijskim protokolom koji sadrži oksaliplatin u bolesnika čiji tumor sadrži mutirani gen RAS ili čiji status RAS nije poznat.
English: What benefits of Vectibix have been shown in studies?
Croatian: Koje su koristi lijeka Vectibix dokazane u ispitivanjima?
English: How does Vectibix work?
Croatian: Kako djeluje Vectibix?
English: • Patients receiving Vectibix in combination with FOLFOX lived for an average of 10.1 months without the disease getting worse in a study of 1,183 previously untreated patients compared with 7.9 months for those receiving FOLFOX alone.
Croatian: • Bolesnici koji su primali lijek Vectibix u kombinaciji s protokolom FOLFOX živjeli su u prosjeku 10,1 mjesec bez pogoršanja bolesti tijekom ispitivanja koje je obuhvatilo 1 183 bolesnika koji nisu prethodno liječeni, u usporedbi sa 7,9 mjeseci u onih koji su primali samo FOLFOX.
English: This is because growth of these types of cells does not depend on EGFR and they can continue to grow uncontrollably even when EGFR is blocked.
Croatian: Čini se da panitumumab ne djeluje na tumorske stanice koje sadrže mutirane (abnormalne) gene RAS zbog toga što rast tih vrsta stanica ne ovisi o EGFR-u, pa one mogu nastaviti nekontrolirano rasti čak i kad je EGFR blokiran.
English: Several bowel cancer studies have shown that Vectibix is effective at prolonging life or slowing disease progression in patients with ‘wild-type' RAS tumours that have spread.
Croatian: Nekoliko ispitivanja provedenih među oboljelima od raka crijeva pokazalo je da je lijek Vectibix učinkovit u pogledu produženja životnog vijeka ili usporavanja napredovanja bolesti u bolesnika čiji tumori imaju gene RAS divljeg tipa i metastazirali su.
English: The active substance in Vectibix, panitumumab, is a monoclonal antibody, a type of protein that has been designed to attach to and block a target called EGFR on certain cells, including some tumour cells.
Croatian: Djelatna tvar lijeka Vectibix, panitumumab, monoklonsko je protutijelo, tj. vrsta proteina koja se ciljano vezuje na i blokira receptor epidermalnog faktora rasta (EGFR) na nekim stanicama, uključujući i neke stanice tumora.
English: Vectibix is used alone or with other cancer medicines in patients with a type of tumour that has normal (‘wild-type') copies of a gene known as RAS.
Croatian: Vectibix se primjenjuje samostalno ili u kombinaciji s drugim lijekovima protiv raka u bolesnika oboljelih od tumora s normalnim kopijama („divljeg tipa”) gena RAS.